H. Michael Shepard is an American cancer

Cancer

Cancer , known medically as a malignant neoplasm, is a large group of different diseases, all involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming malignant tumors, and invade nearby parts of the body. The cancer may also spread to more distant parts of the...

 researcher.

He holds a bachelor's degree from the University of California, Davis

University of California, Davis

The University of California, Davis is a public teaching and research university established in 1905 and located in Davis, California, USA. Spanning over , the campus is the largest within the University of California system and third largest by enrollment...

. He received a Ph.D. from the Indiana University

Indiana University

Indiana University is a multi-campus public university system in the state of Indiana, United States. Indiana University has a combined student body of more than 100,000 students, including approximately 42,000 students enrolled at the Indiana University Bloomington campus and approximately 37,000...

. Dr. Shepard was a Damon Runyon Cancer Research Foundation

Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation is a not-for-profit cancer research organization focused "discovering the talent to discover the cure." The Foundation states that its goals are to: "identify the best and brightest early career scientists in cancer research, accelerate the translation...

 Fellow at Indiana University. He, is a founder, president and CSO of Receptor BioLogix, a California-based biopharmaceutical company focused on developing a newly discovered class of protein therapeutics called Intron Fusion Proteins (IFP) to treat cancer, autoimmune, metabolic and other diseases. Formerly, he was chief scientific officer and vice president of research at Canji, Inc., where he developed the application of the p53 gene product for cancer treatment. While at Genentech, he led the discovery and development of the breast cancer drug, Trastuzumab

Trastuzumab

Trastuzumab is a monoclonal antibody that interferes with the HER2/neu receptor.The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off...

 (trade name: Herceptin).

Dr. Shepard shared the 2006 Alpert Prize for his contribution to the development of the breast cancer therapy Herceptin, the first target-directed cancer treatment for solid tumors.

Dr. Shepard holds over 25 US patents.

Patents

— Methods to treat autoimmune and inflammatory conditions — Method of using an adenoviral vector encoding a retinoblastoma protein to treat hyperproliferating cells — Compositions and methods for treating cells having double minute DNA — Enzyme catalyzed therapeutic activation — Use of tumor necrosis factor as an adjuvant — Methods and compositions for overcoming resistance to biologic and chemotherapy — Monoclonal antibodies directed to the HER2 receptor — Monoclonal antibodies directed to the HER2 receptor — Methods for selectively transducing pathologic mammalian cells using a tumor suppressor gene — Enzyme catalyzed therapeutic agents — HER2 extracellular domain — Organ-specific targeting of cationic amphiphile / DNA complexes for gene therapy — Enzyme catalyzed therapeutic agents — Monoclonal antibodies directed to the HER2 receptor — Application of enzyme prodrugs as anti-infective agents — HER2 extracellular domain — Therapeutic use of the retinoblastoma susceptibility gene product — Method of purification of viral vectors — Monoclonal antibodies directed to the HER2 receptor — Monoclonal antibodies directed to the HER2 receptor — Characterization of a novel anti-p110.sup.RB monoclonal antibody — Monoclonal antibodies directed to the HER2 receptor — Use of tumor necrosis factor (TNF) as an adjuvant — Method and compositions for modulating neovascularization

External links

• Receptor Biologix
• Alpert Foundation